Cancer vaccines

BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines

Retrieved on: 
Wednesday, February 10, 2021
Cancer, Infectious causes of cancer, Papillomavirus, Clinical medicine, Medical specialties, Gynaecological cancer, Vaccines, Cancer vaccines, HPV vaccine, Human papillomavirus infection, Cervical cancer, Vaccine

Left untreated, HPV infection generally leads to cervical cancer (World Health Organization, HPV and Cervical Cancer, 11 November 2020).

Key Points: 
  • Left untreated, HPV infection generally leads to cervical cancer (World Health Organization, HPV and Cervical Cancer, 11 November 2020).
  • In return, Procare Health will have exclusive rights to market and distribute BVX-0918A in the European Union ("EU"), and the United Kingdom.
  • The collaboration with BioVaxys will help Procare Health fuel its product offerings in the gynecological oncology field.
  • BioVaxys and Procare Health will split costs for feasibility, proof-of-concept, and preclinical development for a HPV viral vaccine, as well as a cervical cancer vaccine based on the BioVaxys cancer vaccine platform.

Global Human Papillomavirus (HPV) Vaccine Market Could Exceed $12 Billion By 2027

Retrieved on: 
Wednesday, February 10, 2021
Cancer, Papillomavirus, Clinical medicine, Medical specialties, Infectious causes of cancer, Cancer vaccines, Vaccines, Gynaecological cancer, HPV vaccine, Human papillomavirus infection, Vaccine, Papillomaviridae

The Fortune report projected that The global Human Papillomavirus (HPV) Vaccine market size was valued at USD 3.80 billion in 2019 and is projected to reach USD 12.69 billion by 2027, exhibiting a CAGR of 16.3% during the forecast period.

Key Points: 
  • The Fortune report projected that The global Human Papillomavirus (HPV) Vaccine market size was valued at USD 3.80 billion in 2019 and is projected to reach USD 12.69 billion by 2027, exhibiting a CAGR of 16.3% during the forecast period.
  • "North America (has recently) held the largest HPV vaccines market share with a revenue of USD 1.83 billion.
  • The rise in preference for vaccination and treatment at the nearest healthcare institution will also add impetus to the regional market growth."
  • In return, Procare Health will have exclusive rights to market and distribute BVX-0918A in the European Union ("EU"), and the United Kingdom.

Global Human Papillomavirus (HPV) Vaccine Market Could Exceed $12 Billion By 2027

Retrieved on: 
Wednesday, February 10, 2021
Cancer, Papillomavirus, Clinical medicine, Medical specialties, Infectious causes of cancer, Cancer vaccines, Vaccines, Gynaecological cancer, HPV vaccine, Human papillomavirus infection, Vaccine, Papillomaviridae

The Fortune report projected that The global Human Papillomavirus (HPV) Vaccine market size was valued at USD 3.80 billion in 2019 and is projected to reach USD 12.69 billion by 2027, exhibiting a CAGR of 16.3% during the forecast period.

Key Points: 
  • The Fortune report projected that The global Human Papillomavirus (HPV) Vaccine market size was valued at USD 3.80 billion in 2019 and is projected to reach USD 12.69 billion by 2027, exhibiting a CAGR of 16.3% during the forecast period.
  • "North America (has recently) held the largest HPV vaccines market share with a revenue of USD 1.83 billion.
  • The rise in preference for vaccination and treatment at the nearest healthcare institution will also add impetus to the regional market growth."
  • In return, Procare Health will have exclusive rights to market and distribute BVX-0918A in the European Union ("EU"), and the United Kingdom.

BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines

Retrieved on: 
Wednesday, February 10, 2021
Cancer, Infectious causes of cancer, Papillomavirus, Clinical medicine, Medical specialties, Gynaecological cancer, Vaccines, Cancer vaccines, HPV vaccine, Human papillomavirus infection, Cervical cancer, Vaccine

Left untreated, HPV infection generally leads to cervical cancer (World Health Organization, HPV and Cervical Cancer, 11 November 2020).

Key Points: 
  • Left untreated, HPV infection generally leads to cervical cancer (World Health Organization, HPV and Cervical Cancer, 11 November 2020).
  • In return, Procare Health will have exclusive rights to market and distribute BVX-0918A in the European Union ("EU"), and the United Kingdom.
  • The collaboration with BioVaxys will help Procare Health fuel its product offerings in the gynecological oncology field.
  • BioVaxys and Procare Health will split costs for feasibility, proof-of-concept, and preclinical development for a HPV viral vaccine, as well as a cervical cancer vaccine based on the BioVaxys cancer vaccine platform.

Genocea Announces Publication in Cancer Discovery Highlighting the Advantages of Neoantigen Identification with the ATLAS™ Platform

Retrieved on: 
Thursday, January 28, 2021
Branches of biology, Medical specialties, Clinical medicine, Immune system, Immunology, Cancer vaccines, Genomics, Medical genetics, Immunotherapy, T cell, Antigen, Individualized cancer immunotherapy

This breakthrough improves neoantigen immunotherapies by potentially ensuring they are targeting the right neoantigens and excluding Inhibigens.

Key Points: 
  • This breakthrough improves neoantigen immunotherapies by potentially ensuring they are targeting the right neoantigens and excluding Inhibigens.
  • ATLAS profiling of neoantigen-specific T cell responses in a cohort of lung cancer patients revealed three critical observations.
  • First, many of these tumor-specific helper and killer T cells were inhibitory and shut off neighboring beneficial T cell responses.
  • Our unique ATLAS platform comprehensively profiles each patients T cell responses to potential targets, or antigens, on the tumor.

COVID-19 Vaccine Now Available To Priority Management Residents and Staff in Texas

Retrieved on: 
Friday, January 22, 2021
Nursing, Health, Consumer, Infectious diseases, Seniors, Pharmaceutical, Medicine, COVID-19 vaccine, Medical research, Medical specialties, Health sciences, Vaccination, Vaccine, Vaccines, Cancer vaccines

Priority Management announces that the COVID-19 vaccine is now available to all their facility residents and staff members.

Key Points: 
  • Priority Management announces that the COVID-19 vaccine is now available to all their facility residents and staff members.
  • The vaccine has arrived at most Priority Management facilities.
  • (Photo: Business Wire)
    The Texas Department of Health has convened a COVID-19 Expert Vaccine Allocation Panel to recommend strategies for the distribution of the vaccine across the state geographically.
  • Royse City Medical Lodge is the first Priority Management property and the first non-hospital setting in the North Texas area to administer this important therapy.

Neoantigen-Based Personalized Cancer Therapeutic Vaccines Report 2020: Competitive Landscape and Market Forecast to 2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 8, 2021
Pharmaceutical, Health, Oncology, Cancer vaccines, Branches of biology, Medical specialties, Clinical medicine, Vaccination, Therapeutic vaccines, Vaccine, Vaccines, Genomics

This report delivers an in-depth understanding of the Neoantigen based Personalized Cancer therapeutic Vaccines and the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This report delivers an in-depth understanding of the Neoantigen based Personalized Cancer therapeutic Vaccines and the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • There are 10+ active players involved in developing therapies for Neoantigen-based Personalized Cancer therapeutic Vaccines.
  • Launch of emerging vaccines will significantly impact the Neoantigen-based Personalized Cancer therapeutic Vaccines market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Neoantigen-based Personalized Cancer therapeutic Vaccines.

TCR² Therapeutics Announces 2021 Strategic Priorities and Milestones

Retrieved on: 
Friday, January 8, 2021
Clinical medicine, Medicine, Cancer immunotherapy, Virotherapy, Immunotherapy, Cancer vaccines, Juno Therapeutics

CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced its strategic priorities and anticipated upcoming milestones.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced its strategic priorities and anticipated upcoming milestones.
  • We believe 2021 will be another pivotal year for TCR2, ending with three product candidates in clinical trials, most notably gavo-cel in Phase 2 trials for multiple solid tumor indications.
  • Despite the challenges posed by the ongoing pandemic, we remain focused on the execution of our strategic priorities and bringing meaningful therapies to cancer patients.
  • Pipeline Expansion: TCR2 plans to file an IND for a third TRuC-T cell program in 2021.

Global Opportunity Analysis and Industry Forecast in the Cancer Vaccines Market to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 4, 2021
Pharmaceutical, Health, Oncology, Medical specialties, Vaccination, Branches of biology, Medicine, Vaccines, Virology, Cancer vaccines, Vaccine, Gene delivery, Viral vector, Cancer vaccine, Vaccine therapy

The "Cancer Vaccines Market by Technology Cancer Vaccines, Type, Indication, End User - Global Opportunity Analysis and Industry Forecast, 2019 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Vaccines Market by Technology Cancer Vaccines, Type, Indication, End User - Global Opportunity Analysis and Industry Forecast, 2019 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Increasing administration of prophylactic cancer vaccines and rising investments for the development of new cancer vaccines are expected to fuel the cancer vaccines market growth.
  • Moreover, factors such as emphasis on early diagnosis of cancer, introduction & approval of cancer vaccines and technological developments are expected to boost the demand for cancer vaccines market growth.
  • On the basis of technology, the market is segregated into dendritic cells cancer vaccines, recombinant cancer vaccine, antigen cancer vaccine and viral vector & DNA cancer vaccines.

Global Pediatric Vaccine Market 2020-2025 by Vaccine Type, Technology, Application, Geography, Competitive Analysis and the Impact of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 29, 2020
Health, General Health, Medical specialties, Vaccines, Clinical medicine, Vaccination, Vaccine, Virology, Cancer vaccines, Gavi, Vaccine hesitancy

The "Global Pediatric Vaccine Market (2020-2025) by Vaccine Type, Technology, Application, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pediatric Vaccine Market (2020-2025) by Vaccine Type, Technology, Application, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Additionally, increasing awareness about the importance of pediatric vaccination in the prevention of diseases is expected to fuel market growth.
  • However, the costs attached to immunization and the low level of accessibility in low-income countries restrain the growth of this market.
  • By Vaccine Type, the Monovalent Vaccine is estimated to account for the fastest-growing segment during the forecast period.